Clinical Efficacy of Retreatment with Venetoclax-based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma

Despite the rapidly evolving therapeutic armamentarium leading to improved survival of patients, multiple myeloma (MM) remains incurable in most cases, emphasizing the urgent need for new therapeutic strategies. It has been observed that patients with MM can overexpress anti-apoptotic proteins, including the B-Cell Leukemia/Lymphoma 2 (BCL-2) protein which promotes tumor proliferation and expansion. 1 BCL-2 upregulation has been primarily observed in patients harboring the translocation between chromosomes 11 and 14 (t[11;14]), which is encountered in 15-20% of MM patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research